The Directors of Radiopharm Theranostics Limited (“RAD") are pleased to offer you the opportunity to participate in our Non-Renounceable Entitlement Offer (NREO).
Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company), a developer of a
world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, intends to conduct an equity raising via a 1 for 2.35 non-renounceable entitlement offer of new fully paid ordinary shares in Radiopharm (New Shares) to raise up to approximately $10 million (Entitlement Offer).
The offer price for the Entitlement Offer will be $0.07 per share (Offer Price). The Offer Price represents:
- 23.1% discount to the theoretical ex-rights price (TERP)} of $0.091;
- 30.0% discount to the last traded price of Radiopharm shares on 30 October 2023 of $0.10; and 46.2% discount to the 15-day volume weighted average price (VWAP) of $0.13.
Directors intend to take-up entitlements in part or in full in the Entitlement Offer.
Radiopharm Theranostics believes that an entitlement offer will benefit shareholders who want to maintain their proportional ownership in the Company, as we believe our shareholders should have the first right to participate in the growth of the Company and continue the journey to maximising shareholder wealth.
A non-renounceable entitlement offer is a type of capital raising method used by companies to raise funds from existing shareholders. In this offer, existing shareholders are given the opportunity to purchase additional shares in the company at a discounted price.
However, unlike a renounceable entitlement offer, shareholders cannot sell their entitlements on the market if they do not wish to participate in the offer.
If you have additional questions about the offer, please submit your questions below and one of our Directors will be in touch with you shortlyContact Us